Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D
Andrea Morales Caceres1, Kshitij Kumar Singh2,3, Timo Minssen3
1YORK UNIVERSITY, TORONTO, ONTARIO, CANADA.
Abstract:
The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization's (WHO's) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.
Related Concept Videos
Antimicrobial Effectiveness
Development of Antibiotic Resistance
Microorganisms in Medicine and Therapeutics
Gene Regulation in Microbial Communities: Quorum Sensing
Antibiotic Selection


